Ensysce Biosciences (ENSC) Awarded $2.8M Grant for Multi-Pill Abuse Resistance Platform
- S&P 500, Nasdaq close up 4th straight week as optimism grows
- 'Back in Tech': Investors are Increasing Exposure to Tech and Growth Stocks - BofA
- Rivian Reports Bigger Loss, Says Current Models Won't Qualify for Tax Breaks
- US-listed China Stocks Slip on Delisting Moves, Analyst Sees Short-term Noise
- Salesforce (CRM), Snowflake (SNOW) Rated New Sell at Guggenheim, Oracle (ORCL) at Buy
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) today announced the Company has received a notice of award for the 4th year of funding of a multi-year grant from the National Institute on Drug Abuse (NIDA) for its Multi-Pill Abuse Resistance (MPAR™) Platform. The amount awarded is $2.8 million and the budget start date is July 1, 2022. This brings total funding from NIDA under this grant to $10.8 million. The funding will support the third part of the ongoing Phase 1 clinical trial evaluating the MPAR™ platform.
Lynn Kirkpatrick, CEO of Ensysce Biosciences, commented, "We are honored to receive the final year of the UH3DA047682 award titled ‘PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial' allowing us the continued resources to bring PF614-MPARTM through early clinical development. The receipt of this funding validates our significant progress to date as we move towards realizing our goal of delivering superior pain relief options while also providing abuse and overdose protection for opioid products. Importantly, this is further confirmation of NIDA recognizing the importance and benefits of our TAAPTM and MPARTM technologies."
PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TAAPTM) and overdose protection through multi-pill abuse resistance (MPAR™) technology. TAAPTM chemical modification inactivates the active ingredient in PF614 to provide abuse deterrence, and the combination with the trypsin inhibitor, nafamostat, in MPAR™ provides the additional layer of overdose protection.
As recently reported, the PF614-MPAR-101 overdose protection study examined PF614 administered orally alone or in combination with the trypsin inhibitor nafamostat (MPAR) to healthy volunteers. The early data demonstrated the overdose protection of our MPAR combination product, with reduced release of oxycodone from PF614 in a simulated overdose situation. It also demonstrated the PF614 in the systemic circulation (simulated injection) did not convert to oxycodone. Ensysce believes this is a major step in identifying the first MPAR drug product that will be marketed in the coming years.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Relief Therapeutics and Acer Therapeutics (ACER) Announce EC Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
- BigCommerce (BIGC) Announces Termination of Key Management
- Guardant Health (GH) Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for for ENHERTU
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!